 | Up a level |
Bargagli, Matteo; Liguori, Antonio; Napodano, Cecilia; Baroni, Silvia; Tomasello, Lidia; Pizzolante, Fabrizio; De Matthaeis, Nicoletta; De Ninno, Grazia; Grieco, Antonio; Gasbarrini, Antonio; Gambaro, Giovanni; Ferraro, Pietro Manuel; Miele, Luca (2023). Urinary lithogenic profile of patients with non-alcoholic fatty liver disease. Nephrology, dialysis, transplantation, 38(11), pp. 2652-2654. Oxford University Press 10.1093/ndt/gfad106
Dumitrascu, Dan Lucian; Bakulin, Igor; Berzigotti, Annalisa; Cravo, Marília; Gombošová, Laura; Lukas, Milan; Pietrzak, Anna; Remes-Troche, José María; Romero-Gómez, Manuel; Balmori, Mercedes Amieva; Gonçalves, Tiago Cúrdia; Hamzaoui, Lamine; Juricek, Radovan; Moreira, Leticia; Neubauer, Katarzyna; Surdea-Blaga, Teodora; Tikhonov, Igor N; Trna, Jan; Ianiro, Gianluca; Ponziani, Francesca Romana; ... (2023). Update on the Role of Rifaximin in Digestive Diseases. Journal of gastrointestinal and liver diseases, 32(1), pp. 92-109. "Editura Medicală Universitară "Iuliu Haţieganu" 10.15403/jgld-4871
Bruix, Jordi; Tak, Won-Young; Gasbarrini, Antonio; Santoro, Armando; Colombo, Massimo; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Wiest, Reiner; Reig, María; Wagner, Andrea; Bolondi, Luigi (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European journal of cancer, 49(16), pp. 3412-3419. Elsevier 10.1016/j.ejca.2013.05.028
